Literature DB >> 8232799

A retrospective analysis of pituitary apoplexy.

D C Bills1, F B Meyer, E R Laws, D H Davis, M J Ebersold, B W Scheithauer, D M Ilstrup, C F Abboud.   

Abstract

Thirty-seven patients with pituitary apoplexy were analyzed with an emphasis on clinical presentation and visual outcome. Their mean age was 56.6 years, with a male to female ratio of 2:1. Presenting symptoms included headache (95%), vomiting (69%), ocular paresis (78%), and reduction in visual fields (64%) or acuities (52%). Computed tomographic scanning correctly identified pituitary hemorrhage in only 46% of those scanned. Thirty-six patients underwent transsphenoidal decompression. By immunostaining criteria, null-cell adenomas were the most frequent tumor type (50%). Long-term steroid or thyroid hormone replacement therapy was necessary in 82% and 89% of patients, respectively. Long-term desmopressin therapy was required in 11%, and 64% of the male patients required testosterone replacement therapy. Surgery resulted in improvement in visual acuity deficits in 88%, visual field deficits in 95%, and ocular paresis in 100%. Analysis of the degree of improvement in preoperative visual deficits with the timing of the surgery demonstrated that those who underwent surgery within a week of apoplexy had significant recovery in their visual acuities. In the stable, conscious patient with residual vision in each eye, surgical decompression should be performed as soon as possible, because delays beyond 1 week may retard the return of visual function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232799     DOI: 10.1227/00006123-199310000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  71 in total

1.  Acute visual loss and pituitary apoplexy after surgery.

Authors:  Joseph Abbott; Graham R Kirkby
Journal:  BMJ       Date:  2004-07-24

Review 2.  Neuro-Ophthalmological Emergencies.

Authors:  João Lemos; Eric Eggenberger
Journal:  Neurohospitalist       Date:  2015-10

3.  Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Apoplexy.

Authors:  Rabih Hage; Sheila R Eshraghi; Nelson M Oyesiku; Adriana G Ioachimescu; Nancy J Newman; Valérie Biousse; Beau B Bruce
Journal:  World Neurosurg       Date:  2016-07-17       Impact factor: 2.104

4.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 5.  An approach to the patient with painful ophthalmoplegia, with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone
Journal:  Curr Pain Headache Rep       Date:  2007-08

6.  Pituitary apoplexy: early detection with diffusion-weighted MR imaging.

Authors:  Jeffrey M Rogg; Glenn A Tung; Gordon Anderson; Selina Cortez
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

7.  Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients.

Authors:  Sumit Sinha; Avijit Sarkari; A K Mahapatra; B S Sharma
Journal:  Childs Nerv Syst       Date:  2014-04-29       Impact factor: 1.475

8.  A key role for conservative treatment in the management of pituitary apoplexy.

Authors:  Claire Marx; Muriel Rabilloud; Françoise Borson Chazot; Caroline Tilikete; Emmanuel Jouanneau; Gerald Raverot
Journal:  Endocrine       Date:  2020-09-21       Impact factor: 3.633

9.  An unusual presentation of Nelson's syndrome with apoplexy and subarachnoid hemorrhage.

Authors:  Nurperi Gazioğlu; Pinar Kadioğlu; Eylem Ocal; Haldun Erman; Ziya Akar; Büge Oz
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

10.  Effect of transsphenoidal surgery on decreased visual acuity caused by pituitary apoplexy.

Authors:  Naoya Takeda; Katsuzo Fujita; Shigenori Katayama; Nobuyuki Akutu; Shigeto Hayashi; Eiji Kohmura
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.